PCA3 and prostate cancer: To assess the association of PCA3 expression with clinical endpoints we plotted PCA3 expression in a John Hopkins Medical Institute (JHMI) cohort previously used to validate the Decipher test (JHMI-I) [20] and tagged events for biochemical recurrence (BCR), metastasis (MET) and Prostate Cancer Specific Mortality (PCSM) free survival (Figure 3A).